Research Journal of Microbiology1816-4935xxxx-xxxxScience International10.3923/jm.2015.336.342NasirIdris AbdullahiUsmanYahayaBabayoAdamu72015107Cytomegalovirus (CMV) screening in pregnancy has not been recommended during antenatal clinic days in Nigeria and most countries of the world. However, CMV has been widely accepted as, the viral etiology with the greatest propensity for congenital transmission. Due to CMV ubiquity, seronegative women are highly susceptible to CMV infection and thus, has increased risk of maternal infections and possibly congenital transmission. In view of this, this study aimed to determine the seroprevalence of women, who are anti-CMV IgG seronegative, thus susceptible to CMV infections. We made use of NovalisaTM anti-CMV IgG ELISA kit to screen 182 blood samples of pregnant women attending antenatal clinics of University of Maiduguri Teaching Hospital (UMTH), Maiduguri, Nigeria. Structured questionnaire was used to collect participants’ sociodemographic data. A total of 38 out of 182 subjects were anti-CMV IgG seronegative making a seroprevalence of 20.9%. There was significant statistical association between seronegativity and subjects’ education level and history of previous blood transfusion (p<0.05) but not with age, parity, gravida and gestation age (p>0.05). Findings from our evaluation indicated that many pregnant women were anti-CMV IgG seronegative and thus susceptible to maternal CMV infections. These women have high risk of contacting primary CMV infections and might eventually pose danger to their unborn fetuses in the absence of appropriate preventive measures.]]>Akinbami, A.A., K.A. Rabiu, A.A. Adewunmi, K.O. Wright and A.O. Dosunmu et al.,2011Int. J. Women's Health,3423428Bodeus, M., B. Kabamba-Mukadi, F. Zech, C. Hubinont, P. Bernard and P. Goubau,2010in utero transmission: Follow-up of 524 maternal seroconversions.]]>J. Clin. Virol.,47201202Centers for Disease Control and Prevention,2008Morbidity Mortality Weekly Rep.,576568Enders, G., A. Daiminger, U. Bader, S. Exler and M. Enders,2011J. Clin. Virol.,52244246Feldman, B., Y. Yinon, M.T. Oikawa, R. Yoeli, E. Schiff and S. Lipitz,2011Am. J. Obstet. Gynecol.,205342-e1342-e6Forsgren, M.,2009Euro Surveill,1416Hamdan, H.Z., I.E. Abdelbagi, N.M. Nasser and I. Adam,2011Virol. J., Vol. 8.2011Hyde, T.B., D.S. Schmid and M.J. Cannon,2010Rev. Med. Virol.,20311326Jeon, J., M. Victor, S.P. Adler, A. Arwady and G. Demmler et al.,2006Infect. Dis. Obstet. Gynecol., Vol. 2006.2006Juckstock, J., M. Rothenburger, K. Friese and F. Traunmuller,2015Pharmacology,95209217Kenneson, A. and M.J. Cannon,2007Rev. Med. Virol.,17253276Malek, A., R. Sager, P. Kuhn, K.H. Nicolaides and H. Schneider,1996Am. J. Reprod. Immunol.,36248255Manicklal, S., V.C. Emery, T. Lazzarotto, S.B. Boppana and R.K. Gupta,2013Clin. Microbiol. Rev.,2686102Matos, S.B., R. Meyer and W.F.M. Lima,2010Revista Brasileira de Hematologia e Hemoterapia,315168484Nathanson, N. and W.J. Moss,2013Epidemiology.2013Okwori, A., A. Olabode, E. Emumwen, G. Echeonwu and M. Lugos et al.,2008Internet J. Infect. Dis.,719Rahav, G., R. Gabbay, A. Ornoy, S. Shechtman, J. Arnon and O. Diav-Citrin,2007Emerg. Infect. Dis.,1317911793Revello, M.G., E. Fabbri, M. Furione, M. Zavattoni and D. Lilleri et al.,2011J. Clin. Virol.,50303307Ross, D.S., M. Victor, E. Sumartojo and M.J. Cannon,2008TM survey.]]>J. Women's Health,17849858Sherkat, R,. M. Meidani, H. Zarabian, A. Rezaei and A. Gholamrezaei,2014J. Res. Med. Sci.,9S22S25Vauloup-Fellous, C., M. Berth, F. Heskia, J.M. Dugua and L. Grangeot-Keros,2013® cytomegalovirus (CMV) IgG avidity assay: Determination of new cut-off values based on the study of kinetics of CMV-IgG maturation.]]>J. Clin. Virol.,56118123Vauloup-Fellous, C., O. Picone, A.G. Cordier, I. Parent-du-Chatelet, M.V. Senat, R. Frydman and L. Grangeot-Keros,2009J. Clin. Virol.,46S49S53Yeroh, M., M. Aminu and B.O.P. Musa,2015Afr. J. Cln. Exp. Microbiol.,163744